Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 86, Issue 2, 2009, Pages 117-123

  Sonoki, Kazuo ^a   Iwase, Masanori ^a   Sasaki, Nobuhiro ^a   Ohdo, Shigehiro ^b   Higuchi, Shun ^b   Matsuyama, Naoto ^c   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Azwell Inc   (Japan)

Author keywords

Homocysteine thiolactonase; Lipoprotein associated phospholipase A2; Lysophosphatidylcholine; Paraoxonase; Simvastatin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLDIALKYLPHOSPHATASE; ENZYME; GAMMA THIOBUTYROLACTONE; HOMOCYSTEINE THIOLACTONASE; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PARAOXON; SIMVASTATIN; THIOBUTYROLACTONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHOLIPID BLOOD LEVEL; TREATMENT DURATION;

ADULT; ARYLDIALKYLPHOSPHATASE; BLOOD PRESSURE; BODY MASS INDEX; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LECITHINS; LIPOPROTEINS, LDL; LYSOPHOSPHATIDYLCHOLINES; MALE; MIDDLE AGED; PHOSPHOLIPASES A2; REFERENCE VALUES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 70349783678     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.08.014     Document Type: Article

References (35)

1. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 473-480
2. Hunt J.V., Smith C.C., and Wolff S.P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39 (1990) 1420-1424
3. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96 (1995) 2882-2891
4. Khersonsky O., and Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 (2005) 6371-6382
5. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275 (2000) 3957-3962
6. Ikeda Y., Suehiro T., Inoue M., Nakauchi Y., Morita T., Arii K., et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47 (1998) 598-602
7. Mackness B., Durrington P.N., Abuashia B., Boulton A.J., and Mackness M.I. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin. Sci. 98 (2000) 355-363
8. Kosaka T., Yamaguchi M., Motomura T., and Mizuno K. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin. Chim. Acta 359 (2005) 156-162
9. Lakshman M.R., Gottipati C.S., Narasimhan S.J., Munoz J., Marmillot P., and Nylen E.S. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism 55 (2006) 1201-1206
10. Kopprasch S., Pietzsch J., Kuhlisch E., and Graessler J. Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J. Clin. Endocrinol. Metab. 88 (2003) 1711-1716
11. Sampson M.J., Braschi S., Willis G., and Astley S.B. Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in type II diabetes. Clin. Sci. 109 (2005) 189-197
12. Mastorikou M., Mackness M., and Mackness B. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. Diabetes 55 (2006) 3099-3103
13. Tsuzura S., Ikeda Y., Suehiro T., Ota K., Osaki F., Arii K., et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 53 (2004) 297-302
14. 2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 923-931
15. Sonoki K., Yoshinari M., Iwase M., Iino K., Ichikawa K., Ohdo S., et al. Glycoxidized low-density lipoprotein enhances monocyte chemoattractant protein-1 mRNA expression in human umbilical vein endothelial cells: relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism 51 (2002) 1135-1142
16. Sonoki K., Iwase M., Iino K., Ichikawa K., Ohdo S., Higuchi S., et al. Atherogenic role of lysophosphatidylcholine in low-density lipoprotein modified by phospholipase A2 and in diabetic patients: protection by nitric oxide donor. Metabolism 52 (2003) 308-314
17. 2 and effects of simvastatin treatment. Atherosclerosis 196 (2008) 931-936
18. Billecke S., Draganov D., Counsell R., Stetson P., Watson C., Hsu C., et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28 (2000) 1335-1342
19. Beltowski J., Wojcicka G., and Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress. The possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 170 (2003) 21-29
20. Kosaka T., Yamaguchi M., Soda Y., Kishimoto T., Tago A., Toyosato M., et al. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin. Chim. Acta 296 (2000) 151-161
21. Ahmed Z., Ravandi A., Maguire G.F., Emili A., Draganov D., La Du B.N., et al. Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. Biochem. Biophys. Res. Commun. 290 (2002) 391-396
22. Marathe G.K., Zimmerman G.A., and McIntyre T.M. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem. 278 (2003) 3937-3947
23. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J. Nutr. 130 (2000) 377S-381S
24. Naruszewicz M., Mirkiewicz E., Olszewski A.J., and McCully K.S. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophases. Nutr. Metab. Cardiovasc. Dis. 4 (1994) 70-77
25. Ferretti G., Bacchetti T., Moroni C., Vignini A., Nanetti L., and Curatola G. Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J. Cell. Biochem. 92 (2004) 351-360
26. Ferretti G., Bacchetti T., Busni D., Rabini R.A., and Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J. Clin. Endocrinol. Metab. 89 (2004) 2957-2962
27. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 13 (1999) 2277-2283
28. Kordonouri O., James R.W., Bennetts B., Chan A., Kao Y.L., Danne T., et al. Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 50 (2001) 657-660
29. Hedrick C.C., Thorpe S.R., Fu M.X., Harper C.M., Yoo J., Kim S.M., et al. Glycation impairs high-density lipoprotein function. Diabetologia 43 (2000) 312-320
30. Zhou H., Tan K.C., Shiu S.W., and Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol. Dial. Transplant. 23 (2008) 927-933
31. Deakin S.P., and James R.W. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. 107 (2004) 435-447
32. Tomas M., Senti M., Garcia-Faria F., Vila J., Torrents A., Covas M., et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2113-2119
33. 2 levels. Atherosclerosis 182 (2005) 193-198
34. Sonoki K., Iwase M., Sasaki N., Ohdo S., Higuchi S., Takata Y., et al. Secretory PLA2 inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFalpha-stimulated human endothelial cells. Br. J. Pharmacol. 153 (2008) 1399-1408
35. Boyd H.F., Fell S.C., Hickey D.M., Ife R.J., Leach C.A., Macphee C.H., et al. Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones. Bioorg. Med. Chem. Lett. 12 (2002) 51-55